Background. Proteases can increase the activity of the epithelial sodium channel (ENaC) by cleaving its α-or γ-subunit. However, evidence so far comes only from studies in vitro in either heterologous expression systems or isolated nephron segments. The present study has tested whether exposure to a luminal protease can alter sodium reabsorption along the rat collecting duct in vivo. Methods. Rats on normal laboratory chow were prepared for renal micropuncture. Late distal tubules of superficial nephrons were microinjected and perfused twice (3 nL min
A B S T R AC T
Background. Proteases can increase the activity of the epithelial sodium channel (ENaC) by cleaving its α-or γ-subunit. However, evidence so far comes only from studies in vitro in either heterologous expression systems or isolated nephron segments. The present study has tested whether exposure to a luminal protease can alter sodium reabsorption along the rat collecting duct in vivo. Methods. Rats on normal laboratory chow were prepared for renal micropuncture. Late distal tubules of superficial nephrons were microinjected and perfused twice (3 nL min −1 for 3-6 min) with a solution similar to native tubular fluid, but containing 14 [C]inulin and 22 Na. The first perfusion was either a control solution or solution containing amiloride 1 mM or hydrochlorothiazide (HCTZ ) 1 mM; the second perfusion was either a control solution (time control) or a solution containing chymotrypsin 2 µg mL −1 ± aprotinin 100 µg mL −1 or amiloride 1 mM or HCTZ 1 mM. Urinary recoveries of 14 [C]inulin and 22 Na were recorded. Results. In time controls, the Na/In ratio did not change significantly (32.2 ± 3.4% versus 34.5 ± 3.1%). In contrast, chymotrypsin reduced the ratio from 33.3 ± 3.8% to 25.5 ± 2.5% (P < 0.05), indicating an increase in sodium reabsorption. When co-injected with chymotrypsin, the protease inhibitor aprotinin abolished the stimulatory effect of chymotrypsin on sodium reabsorption (31.7 ± 3.4% versus 32.1 ± 2.1%), while aprotinin alone had no effect. When chymotrypsin was co-injected with HCTZ, the Na/In ratio decreased from 36.8 ± 2.3% to 28.0 ± 3.4% (P < 0.05), whereas when given with amiloride, there was no change in the ratio (45.8 ± 3.4% versus 45.5 ± 2.3%), indicating that stimulation of sodium reabsorption by chymotrypsin was ENaCdependent.
Conclusions. These findings demonstrate proteolytic activation of ENaC in vivo, and suggest that changes in protease activity of the glomerular filtrate and tubular fluid in health or disease could affect net renal sodium excretion.
I N T R O D U C T I O N
A major function of the kidney is to maintain sodium (Na + ) homeostasis by regulatory changes in the activity of several key Na + -transporting processes along the nephron.
Alterations in these Na + transport mechanisms usually underlie disturbances in Na + balance. In the aldosteroneresponsive epithelial cells of the distal nephron, the epithelial sodium channel (ENaC) is the rate-limiting step in transepithelial Na + transport, and is critical in the control of Na + balance, blood volume and blood pressure [1] . ENaC is composed of three homologous subunits: α, β and γ. Each subunit has short cytosolic N-and C-terminal domains, and two transmembrane domains separated by a large extracellular region.
In the last decade, serine proteases have been identified as novel regulators of Na + transport [2, 3] . Serine proteases are proteolytic enzymes present in viruses, bacteria and eukaryotes, and they are involved in the regulation of several physiological processes, including blood coagulation, digestion and inflammation [4] . However, altered serine protease levels in human urine, for example kallikrein [5, 6] , CAP1/prostasin [7, 8] and plasmin [9] , have also been linked to hypertension and renal disease associated with disturbed Na + and water balance, such as the nephrotic syndrome [10, 11] . Studies in patients and in rats in vivo have shown that increased levels of aldosterone (in primary hyperaldosteronism or by aldosterone infusion), a major hormonal regulator of distal nephron Na + reabsorption, can induce hypertension and stimulate urinary excretion of CAP1/prostasin [7, 8] . Moreover, urinary kallikrein excretion has also been reported to increase in response to aldosterone in rats and to decrease following adrenalectomy [12] . Aldosterone stimulation in rats increases the expression of proteolytic fragments of α and γENaC subunits in the kidney, similar to the cleavage of the α-subunit by furin, and the γ-subunit by furin and a second serine protease [13, 14] .
Plasmin is detectable in the urine of patients with the nephrotic syndrome, but not usually in normal urine, although urokinase and plasminogen activator are present [15] . In glomerular disease with heavy proteinuria, sufficient plasminogen can cross the glomerular filtration barrier and be converted to plasmin by tubular fluid urokinase [9] . Plasmininduced activation of ENaC might thus contribute to Na + retention, extracellular fluid volume expansion and hypertension in the nephrotic syndrome. Therefore, the question arises whether a protease-mediated change in Na + transport in the kidney is physiologically important and/or pathologically relevant in vivo.
Recent data support the concept that proteases can increase the activity of ENaC [16] , although these data are from studies in vitro, using mainly electrophysiological techniques in heterologous expression systems or in isolated nephron segments [16, 17] . While proteolytic activation of ENaC in the aldosterone-sensitive distal nephron might have optimized channel activity (open probability) [18] , the effect of serine proteases on Na + transport could be through the cleavage of other Na + transport proteins or receptors that regulate them. Hence, the aim of the present study was to assess the effect of the archetypal protease chymotrypsin on Na + reabsorption in normal rat collecting ducts in vivo.
M AT E R I A L S A N D M E T H O D S

Animals
All animal procedures were approved by the Institutional Ethical Committee and were carried out under the animals (Scientifics Procedures) Act 1986 (UK Home Office License RVC/09/192). Male Sprague-Dawley rats were maintained on a normal diet (Na + content 140 mmol/kg dry weight; n = 69 rats); on the day of study, they were anaesthetized with Inactin (120 mg kg −1 i.p.; Sigma Ltd., Poole, Dorset, UK) and prepared surgically for micropuncture of the left kidney [19] .
Tubule microinjection experiments
We have described this technique in a previous publication [19] . Throughout each experiment, rats were infused intravenously with a NaCl solution (150 mM) at a rate of 5 mL h ; PerkinElmer, Bucks, UK), 22 Na (25 µCi mL
; PerkinElmer), and 0.07% FD&C Blue dye, pH 6.50. For a chloride (Cl − ) perfusate, sodium glutamate (50 mM) and potassium glutamate (10 mM) were substituted for NaCl and KCl, respectively.
To monitor [ 14 C]inulin and 22 Na recoveries, urine was collected from the ureter of the microinjected kidney directly into vials containing scintillant (Aquasol 2; PerkinElmer) for a total of 20 min after the start of microinjection. Urine was also collected from the contralateral kidney for the determination of overall Na + excretion (measured by flame photometry; model 543, Instrumentation Laboratory, Warrington, Cheshire, UK).
Each late distal tubule was perfused twice, first with the control perfusate (described above) or a perfusate containing amiloride or hydrochlorothiazide (HCTZ), then with one of the following perfusates: (i) control perfusate (time-control experiments); (ii) perfusate containing α-chymotrypsin [TLCK-treated (1-chloro-3-tosylamido-7-amino-2-heptanone) Type VII from bovine pancreas −2 µg mL −1
; Sigma]; (iii) perfusate containing the protease inhibitor aprotinin (100 µg mL −1 ; Sigma); (iv) perfusate containing the protease inhibitor aprotinin (100 µg mL The results are presented as individual paired values or as means ± SE. Statistical comparisons between the first and second values from paired perfusions were made using Student's paired t-test; a one-tail test was used for amiloride and HCTZ, and a two-tail test for all other comparisons. A value of P < 0.05 was considered statistically significant. (For Cl − -free solutions; to compare Figure 1A with Figure 4A and B, ANOVA was used followed by Bonferroni's post-hoc test.)
R E S U LT S
Urine flow and sodium excretion rates (in the contralateral kidney only) were 7.4 ± 0.8 µL min −1 and 1.1 ± 0.2 µmol min −1 , respectively. With the control perfusate in the four different groups, we have shown that almost 30% of the 22 Na delivered to the late distal tubule was excreted in the final urine. In the timecontrol experiments, there was no change in the Na/In recovery ratio ( Figure 1A ). On addition of chymotrypsin (2 µg mL −1 ) to the perfusate, a significant increase in Na + reabsorption was observed, the Na/In recovery ratio decreasing in 18 of 24 pairs of perfusions ( Figure 1B) . (Note that the n number is greater for chymotrypsin perfusions than for other perfusions, because the former were used as a 'positive control' for the later part of the study.)
To assess the role of chymotrypsin in the increase of 22 Na reabsorption observed in Figure 1B , we perfused a solution containing the protease inhibitor aprotinin alone or together with chymotrypsin. An addition of aprotinin alone to the perfusate did not affect Na + reabsorption ( Figure 1C ). When co-injected with chymotrypsin, aprotinin completely abolished the effect of chymotrypsin on Na + reabsorption, the Na/In recovery ratio being similar to the control period ( Figure 1D) .
To assess the role of ENaC in the increase of 22 Na reabsorption seen in Figure 1B , we perfused with a solution containing the inhibitor of ENaC amiloride, alone or together with chymotrypsin. As expected, addition of amiloride to the perfusate caused a significant increase in the Na/In recovery ratio, indicating reduced Na + reabsorption (Figure 2A ). When co-injected with chymotrypsin, the Na/In recovery ratio did not change significantly, remaining stable and similar to amiloride alone ( Figure 2B ), indicating that chymotrypsin-stimulated Na + reabsorption is mediated by increased ENaC activity ( Figure 1B ).
An electroneutral thiazide-sensitive Na-Cl transporter, the Na + -dependent Cl − /HCO 3 − exchanger (NDCBE) SLC4A8, working in parallel with the Na + -independent Cl − /HCO 3 − exchanger ( pendrin) SLC26A4, has been described recently in the cortical collecting duct of mice [20] . Therefore, we tested the effects of the thiazide diuretic HCTZ and of a Cl − -free solution on the response to chymotrypsin.
An addition of HCTZ (1 mM) to the perfusate caused a small, but significant increase in the Na/In recovery ratio ( Figure 3A) , indicating slight inhibition of Na + reabsorption. However, when co-injected with chymotrypsin, a significant stimulatory effect of chymotrypsin was still observed, the Na/ In recovery ratio decreasing in 12 of 15 pairs of perfusions ( Figure 3B) .
Using a Cl − -free perfusate, in the time-control experiments, there was no change in the Na/In recovery ratio ( Figure 4A ), although the mean value was slightly, but significantly, lower than with the Na + -containing perfusate ( Figure 4A and B versus Figure 1A ; P < 0.01). However, addition of chymotrypsin to the perfusate did not stimulate Na + reabsorption, producing no significant change in the Na/ In ratio ( Figure 4B ).
D I S C U S S I O N
This may be the first study to provide evidence in vivo that ENaC can be activated by extracellular luminal application of a serine protease. Using the renal tubule microinjection technique in vivo [19] , we have shown that the archetypal serine protease chymotrypsin can stimulate the reabsorption of Na + in the distal nephron, known to express ENaC.
As the study of Morimoto et al. showed that the serine protease trypsin could enhance net sodium reabsorption along the isolated perfused rabbit tubule [21] , several studies have reported that ENaC activity can be affected by extracellular serine proteases. Vallet et al. identified an endogenous serine protease CAP1 involved in the regulation of ENaC activity in A6 cells in culture [3] , a cell line with properties similar to the mammalian collecting duct principal cell. A more recent study using the whole cell patch-clamp technique has shown that in native tissue, luminal application of trypsin can stimulate an amiloride-sensitive current in impaled principal cells of split-open tubules (connecting tubule and cortical collecting duct) [17] . However, in this study the authors found significant variability in trypsin's stimulatory effect, ranging from no detectable effect to a 2-fold increase in ENaC-mediated amiloride-sensitive whole cell current, with an average stimulatory effect of ∼30%. Our results also demonstrate variability in chymotrysin's stimulatory effect on Na + reabsorption, corresponding to a mean increase of ∼10%; in a previous late distal tubule microinjection study of ENaC regulation by ATP in vivo, we found a similar degree of variability in Na + reabsorption [19] . The endogenous serine protease tissue kallikrein has also been shown to stimulate ENaC-mediated Na + uptake by principal cells of the isolated and microperfused cortical collecting duct in vitro [22] . Plasmin, another endogenous serine protease, can stimulate ENaC in M-1 cells [9] . Thus, several studies have shown that luminal serine proteases can increase amiloride-sensitive short-circuit current across collecting duct principal cells, suggesting a physiologically relevant functional interaction with ENaC. However, these studies have all been in vitro; the present study confirms that chymotrypsin can enhance intact distal nephron Na + transport in vivo, and that this effect is amiloride-sensitive, and therefore, ENaCmediated.
Proteolytic activation of ENaC may be more likely to occur in states of heavy proteinuria, such as the nephrotic syndrome, in which there is an increase in intrinsic and aldosterone-independent Na + reabsorption [23] , and urinary plasmin is detectable [9] . In puromycin aminonucleoside (PAN)-induced nephrosis, a rat model of the nephrotic syndrome, adrenal steroid-clamped animals do not show any increase in the expression of ENaC, despite increased sodium and water retention [24] ; compatible with increased ENaC activity. Again, plasminogen and plasmin are detectable in the urine of rats with PAN-induced nephrosis [9] . Cleavage of ENaC's α-and/or γ-subunits induced by either trypsin or prostasin releases an inhibitory domain from the extracellular loops of the α-and γ-subunits of ENaC [25, 26] . Prevention or reversal of Na + self-inhibition may also contribute to ENaC activation by proteases [27, 28] ; more recent experiments have shown that extracellular cleavage of the γ-subunit is important in the proteolytic activation of ENaC [29, 30] .
Aldosterone itself may also act by increasing proteolytic activation of ENaC. In addition to its effect on α-ENaC protein abundance, redistribution of ENaC to the apical membrane of the collecting duct principal cells, there is a reduction of the molecular weight of γ-subunit in the rat kidney [14] . Furthermore, in rats infused with aldosterone, or in patients with primary hyperaldosteronism, an increase in urinary prostasin has been reported [7] . Using tissue kallikrein knockout mice, an anti-natriuretic effect of tissue kallikrein has been demonstrated, which is again consistent with proteolytic activation of ENaC [22] . Moreover, an early report by Geller et al. [12] showed that salt restriction or mineralocorticoid administration in rats significantly increased urinary kallikrein excretion.
Thus, increased membrane expression of ENaC is not necessary for an increase in Na + reabsorption in vivo. On a normal-sodium diet, when membrane expression is less abundant and ENaC is reduced, Caldwell et al. have shown that serine proteases can activate the surface-expressed, but near-silent, ENaC [31] . Nesterov et al. have also shown in the mouse distal nephron in vitro that trypsin has a similar effect on Na + transport, whether animals are on a normal or lowsodium diet [17] .
In the present study, we have shown that in rats on a normal laboratory diet there is potential for protease activation of ENaC. When used alone, the chymotrypsin inhibitor aprotinin appeared to have no effect on Na + reabsorption. This could be interpreted in several ways. It may indicate that under normal conditions, the proteolytic activity of tubular fluid is low or that aprotinin has no effect on those ENaC already activated, or that there are no proteases to inhibit in the artificial perfusate; however, the latter seems less likely with the microinjection technique in vivo, because the injection site is proximal to the confluence of other non-perfused late distal tubules that feed into a single collecting duct. Another possibility to consider in our experiments is that proteases may activate other Na + -related transport mechanisms or receptors. Protease-activated receptors have been identified in the proximal tubule, thick ascending limb and cultured collecting duct cells, but are located basolaterally [2] . However, a recently described model of Na + reabsorption in the collecting duct links two apically expressed bicarbonate transporters present in β-intercalated cells, which are both Cl − -dependent--one Na + -dependent (NDCBE) and the other Na + -independent ( pendrin)--and work in parallel 14 C]inulin (means ± SE) for the four groups of perfusions ranged from 100 ± 2 to 102 ± 3%. NS, not significant. 14 C]inulin (means ± SE) for the four groups of perfusions ranged from 98 ± 2 to 102 ± 3%. NS, not significant. [20] . While we could demonstrate a small inhibitory effect of HCTZ on Na + -reabsorption, we found no evidence for an effect of chymotrypsin on this thiazide-sensitive transport mechanism. However, when we used a Cl − -free perfusate (bearing in mind the comment above that several distal tubules can feed a single collecting duct), we found not only a slight increase in Na + reabsorption compared with the Na + -containing perfusate, but also that chymotrypsin no longer had its stimulatory effect. We can only speculate on what the explanation for these findings might be, but ENaC is known to exhibit self-inhibition by Na + and removal of Na + may potentiate its activity [27] . Moreover, Collier and Synder have shown, in a similar manner to Na + feedback, that a low extracellular Cl − concentration increases ENaC activity [32] . This could explain our observed increase in Na + reabsorption and failure of chymotrysin to increase it further; indeed, this might suggest that the Cl − -inhibitory sites are in some way related to the sites of proteolytic activation [33] .
Finally, our findings confirm, and demonstrate in vivo, that Na + reabsorption along the late distal tubule and collecting duct of the rat can be enhanced by luminal exposure to a serine protease, and that this stimulation is mediated by activation of ENaC. While this mechanism may make only a limited contribution to the control of Na + reabsorption along the distal nephron, it might become significant in some diseases and become the therapeutic target. Proteinuric renal disease has already been mentioned, but hypertension is another possibility. Maekawa et al. have shown that camostat mesilate, a synthetic serine protease inhibitor, can inhibit CAP1/prostasin activity and decrease Na + transport in a cortical collecting duct cell line in vitro; oral administration of this compound to Dahl-salt-sensitive rats on a high-salt diet, a model of salt-sensitive hypertension, reduced blood pressure and decreased hypertension-associated renal injury [34] . Additional support for a physiological and pathophysiology role of proteolytic activation of ENaC is the report that the gene for furin, an enzyme that cleaves and activates ENaC [25, 28] , is one of several genes linked to blood pressure regulation in a recent genome-wide association study [35] . Thus, targeting all, or some, these proteases, if they can be better defined, may be suitable drug targets; although this will require the investigation of more disease models in which these proteases can be implicated.
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